Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with <i>ex vivo</i> chemosensitivityEsther Onecha, Rosa Ayala, Elena Magro et al.|British Journal of Haematology|2020Cited by 14
Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasmsAlicia Arenas Cortés, Joaquín Martínez‐López, Rosa Ayala et al.|Haematologica|2018Cited by 9
Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemiaJoaquín Martínez‐López, Juan Ballesteros, Pau Montesinos et al.|Medicine International|2022Cited by 4
Ruxolitinib in Combination with Nilotinib and Prednisolone, a New Synergistic Approach to Treat MyelofibrosisAlicia Arenas, Joaquín Martínez‐López, Pilar Hernández-Campo et al.|Blood|2014Cited by 1